Comparing today's PR in the section "About Brilaci
Post# of 72440
"Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials for other clinical indications, providing an established safety and efficacy profile, thereby potentially enabling it to rapidly help address the emerging worldwide coronavirus crisis, developed both as an intravenous medicine and as a possible vaccine."
The other key note that has been consistent is the sentence:
"The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants to further evaluate and potentially advance Brilacidin’s clinical development as a novel COVID-19 treatment." BP interest could be for COVID-19, or B-IBD Oral or B-OM separately or packaged as a much larger agreement. I personally don't understand why IPIX would need BP to be the middle man regarding COVID-19 unless it was part of a much bigger deal.
Interesting and exciting time to be an IPIX investor!